Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

VYXEOS

CYTARABINE; DAUNORUBICIN

Standard Dose
100MG;44MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview VYXEOS is listed in Drugs@FDA under application 209401 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient CYTARABINE; DAUNORUBICIN Form and strength POWDER;INTRAVENOUS - 100MG;44MG Sponsor JAZZ PHARMS THERAP Submission history Latest submission status date: 2026-01-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview VYXEOS is listed in Drugs@FDA under application 209401 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient CYTARABINE; DAUNORUBICIN Form and strength POWDER;INTRAVENOUS - 100MG;44MG Sponsor JAZZ PHARMS THERAP Submission history Latest submission status date: 2026-01-27 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.